Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
May 01, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	20,120	$134.54	845,986
May 15, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Open market or private sale of non-derivative or derivative security	9,851	$977.42	848,105
May 15, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Open market or private sale of non-derivative or derivative security	6,885	$976.56	857,956
Dec 14, 2011	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	38,516	$51.18	860,754
May 15, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Open market or private sale of non-derivative or derivative security	5,225	$975.60	864,841
May 01, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	100	$133.95	866,106
Mar 26, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	1,010	$121.09	866,206
Mar 26, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	32,140	$120.21	867,216
May 15, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Open market or private sale of non-derivative or derivative security	4,778	$974.47	870,066
Dec 14, 2010	YANCOPOULOS GEORGE Director, EVP CSO & Pres Regn Res Labs	Director, EVP CSO & Pres Regn Res Labs	Form 4/A	Grant, award or other acquisition pursuant to Rule 16b-3(d)	250,000	--	870,375

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media